Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis

Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases that ultimately results in the need for liver transplantation in most patient...

Full description

Bibliographic Details
Main Author: Dong-Won Ahn
Format: Article
Language:English
Published: Jin Publishing & Printing Co. 2020-05-01
Series:The Korean Journal of Gastroenterology
Subjects:
Online Access:http://www.kjg.or.kr/journal/view.html?uid=5575&vmd=Full
_version_ 1819044384517128192
author Dong-Won Ahn
author_facet Dong-Won Ahn
author_sort Dong-Won Ahn
collection DOAJ
description Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases that ultimately results in the need for liver transplantation in most patients. Imaging studies, such as MRCP, have an essential role in the diagnosis of most cases of PSC. PSC is usually accompanied by inflammatory bowel disease, and there is a high risk of cholangiocarcinoma and colorectal cancer in PSC. No medical therapies have been proven to delay the progression of PSC. Endoscopic intervention for tissue diagnosis or biliary drainage is frequently required in cases of PSC with a dominant stricture, acute cholangitis, or clinically suspected cholangiocarcinoma. PBC is a chronic inflammatory autoimmune cholestatic liver disease, which, when untreated, will culminate in end-stage biliary cirrhosis requiring liver transplantation. A diagnosis is usually based on the presence of serum liver tests indicative of cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse in PBC, and risk stratification is important for ensuring that all patients receive a personalized approach to their care. Medical therapy using ursodeoxycholic acid or obeticholic acid has an important role in reducing the progression to end-stage liver disease in PBC.
first_indexed 2024-12-21T10:11:49Z
format Article
id doaj.art-93308a2a220647eeb1f9039af7d00937
institution Directory Open Access Journal
issn 1598-9992
2233-6869
language English
last_indexed 2024-12-21T10:11:49Z
publishDate 2020-05-01
publisher Jin Publishing & Printing Co.
record_format Article
series The Korean Journal of Gastroenterology
spelling doaj.art-93308a2a220647eeb1f9039af7d009372022-12-21T19:07:41ZengJin Publishing & Printing Co.The Korean Journal of Gastroenterology1598-99922233-68692020-05-0175524625610.4166/kjg.2020.75.5.246Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary CholangitisDong-Won Ahn0https://orcid.org/0000-0002-6641-2177Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, KoreaPrimary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases that ultimately results in the need for liver transplantation in most patients. Imaging studies, such as MRCP, have an essential role in the diagnosis of most cases of PSC. PSC is usually accompanied by inflammatory bowel disease, and there is a high risk of cholangiocarcinoma and colorectal cancer in PSC. No medical therapies have been proven to delay the progression of PSC. Endoscopic intervention for tissue diagnosis or biliary drainage is frequently required in cases of PSC with a dominant stricture, acute cholangitis, or clinically suspected cholangiocarcinoma. PBC is a chronic inflammatory autoimmune cholestatic liver disease, which, when untreated, will culminate in end-stage biliary cirrhosis requiring liver transplantation. A diagnosis is usually based on the presence of serum liver tests indicative of cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse in PBC, and risk stratification is important for ensuring that all patients receive a personalized approach to their care. Medical therapy using ursodeoxycholic acid or obeticholic acid has an important role in reducing the progression to end-stage liver disease in PBC.http://www.kjg.or.kr/journal/view.html?uid=5575&vmd=Fullprimary sclerosing cholangitisprimary biliary cholangitischolangiocarcinomaursodeoxycholic acidliver transplantation
spellingShingle Dong-Won Ahn
Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
The Korean Journal of Gastroenterology
primary sclerosing cholangitis
primary biliary cholangitis
cholangiocarcinoma
ursodeoxycholic acid
liver transplantation
title Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
title_full Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
title_fullStr Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
title_full_unstemmed Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
title_short Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
title_sort novel insights of primary sclerosing cholangitis and primary biliary cholangitis
topic primary sclerosing cholangitis
primary biliary cholangitis
cholangiocarcinoma
ursodeoxycholic acid
liver transplantation
url http://www.kjg.or.kr/journal/view.html?uid=5575&vmd=Full
work_keys_str_mv AT dongwonahn novelinsightsofprimarysclerosingcholangitisandprimarybiliarycholangitis